Requirement for Arf6 in breast cancer invasive activities

  • Shigeru Hashimoto
    Department of Molecular Biology, Osaka Bioscience Institute, Osaka 565-0874, Japan; Laboratory of Molecular Cell Biology, Graduate School of Biostudies, Kyoto University, Kyoto 606-8502, Japan; and Laboratory of Molecular Pathogenesis, Nagoya University Graduate School of Medicine, Nagoya 466-8550, Japan
  • Yasuhito Onodera
    Department of Molecular Biology, Osaka Bioscience Institute, Osaka 565-0874, Japan; Laboratory of Molecular Cell Biology, Graduate School of Biostudies, Kyoto University, Kyoto 606-8502, Japan; and Laboratory of Molecular Pathogenesis, Nagoya University Graduate School of Medicine, Nagoya 466-8550, Japan
  • Ari Hashimoto
    Department of Molecular Biology, Osaka Bioscience Institute, Osaka 565-0874, Japan; Laboratory of Molecular Cell Biology, Graduate School of Biostudies, Kyoto University, Kyoto 606-8502, Japan; and Laboratory of Molecular Pathogenesis, Nagoya University Graduate School of Medicine, Nagoya 466-8550, Japan
  • Miwa Tanaka
    Department of Molecular Biology, Osaka Bioscience Institute, Osaka 565-0874, Japan; Laboratory of Molecular Cell Biology, Graduate School of Biostudies, Kyoto University, Kyoto 606-8502, Japan; and Laboratory of Molecular Pathogenesis, Nagoya University Graduate School of Medicine, Nagoya 466-8550, Japan
  • Michinari Hamaguchi
    Department of Molecular Biology, Osaka Bioscience Institute, Osaka 565-0874, Japan; Laboratory of Molecular Cell Biology, Graduate School of Biostudies, Kyoto University, Kyoto 606-8502, Japan; and Laboratory of Molecular Pathogenesis, Nagoya University Graduate School of Medicine, Nagoya 466-8550, Japan
  • Atsuko Yamada
    Department of Molecular Biology, Osaka Bioscience Institute, Osaka 565-0874, Japan; Laboratory of Molecular Cell Biology, Graduate School of Biostudies, Kyoto University, Kyoto 606-8502, Japan; and Laboratory of Molecular Pathogenesis, Nagoya University Graduate School of Medicine, Nagoya 466-8550, Japan
  • Hisataka Sabe
    Department of Molecular Biology, Osaka Bioscience Institute, Osaka 565-0874, Japan; Laboratory of Molecular Cell Biology, Graduate School of Biostudies, Kyoto University, Kyoto 606-8502, Japan; and Laboratory of Molecular Pathogenesis, Nagoya University Graduate School of Medicine, Nagoya 466-8550, Japan

抄録

<jats:p> In most human breast cancer cell lines, there is a direct correlation between their <jats:italic>in vivo</jats:italic> invasive phenotypes and <jats:italic>in vitro</jats:italic> invasion activities. Here, we found that ADP-ribosylation factor 6 (Arf6) is localized at the invadopodia of the cultured breast cancer cells MDA-MB-231, and its suppression by a small-interfering RNA duplex effectively blocks the invasive activities of the cells, such as invadopodia formation, localized matrix degradation and Matrigel transmigration but not the cell-adhesion activity. We also found that the GTP hydrolysis-defective mutant Arf6(Q67L) and the GTP-binding defective mutant Arf6(T27N) both blocked these invasive activities but not cell adhesion, suggesting the necessity of continued activation and cycling of the Arf6 GTPase cycle in invasion. Among the different human breast cancer cell lines that we examined, cell lines with high invasive activities expressed higher amounts of Arf6 protein than those in weakly invasive and noninvasive cell lines, although no notable correlation was found between Arf6 mRNA expression levels and invasive activities. Moreover, Matrigel-transmigration activity of all of these invasive cells was blocked effectively by an Arf6 small-interfering RNA duplex. Hence, Arf6 appears to be an integral component of breast cancer invasive activities, and we propose that Arf6 and the intracellular machinery regulating Arf6 during invasion should be considered as therapeutic targets for the prevention of breast cancer invasion. </jats:p>

収録刊行物

被引用文献 (34)*注記

もっと見る

関連プロジェクト

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ